ANI Pharmaceuticals Inc (NASDAQ:ANIP) Given Consensus Rating of “Buy” by Analysts

Shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) have been given an average recommendation of “Buy” by the eight analysts that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $84.25.

A number of equities analysts have recently issued reports on the company. ValuEngine downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Guggenheim assumed coverage on ANI Pharmaceuticals in a research report on Thursday, September 12th. They set a “buy” rating and a $76.00 price target on the stock. BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. Finally, Zacks Investment Research raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, September 12th.

In other news, major shareholder Meridian Venture Partners Ii L sold 7,579 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $68.21, for a total transaction of $516,963.59. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 98,451 shares of company stock worth $7,006,801 in the last three months. Corporate insiders own 24.70% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Hancock Whitney Corp boosted its position in ANI Pharmaceuticals by 1.4% during the second quarter. Hancock Whitney Corp now owns 11,446 shares of the specialty pharmaceutical company’s stock valued at $941,000 after purchasing an additional 155 shares in the last quarter. Nomura Holdings Inc. boosted its position in ANI Pharmaceuticals by 34.1% during the second quarter. Nomura Holdings Inc. now owns 375,449 shares of the specialty pharmaceutical company’s stock valued at $31,071,000 after purchasing an additional 95,462 shares in the last quarter. Royal Bank of Canada boosted its position in ANI Pharmaceuticals by 186.8% during the second quarter. Royal Bank of Canada now owns 2,765 shares of the specialty pharmaceutical company’s stock valued at $227,000 after purchasing an additional 1,801 shares in the last quarter. First Manhattan Co. boosted its position in ANI Pharmaceuticals by 22.8% during the second quarter. First Manhattan Co. now owns 294,852 shares of the specialty pharmaceutical company’s stock valued at $24,236,000 after purchasing an additional 54,686 shares in the last quarter. Finally, United Services Automobile Association bought a new stake in ANI Pharmaceuticals during the second quarter valued at about $224,000. 70.77% of the stock is currently owned by institutional investors.

ANIP stock traded down $0.27 during midday trading on Tuesday, reaching $72.42. The company’s stock had a trading volume of 107,952 shares, compared to its average volume of 173,278. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.74 and a current ratio of 1.01. The stock has a fifty day simple moving average of $70.47 and a two-hundred day simple moving average of $71.95. ANI Pharmaceuticals has a 1 year low of $36.92 and a 1 year high of $86.96. The firm has a market capitalization of $879.26 million, a price-to-earnings ratio of 15.71 and a beta of 2.22.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.18 by $0.26. ANI Pharmaceuticals had a return on equity of 29.53% and a net margin of 8.14%. The business had revenue of $54.36 million for the quarter, compared to the consensus estimate of $55.20 million. During the same quarter in the prior year, the company earned $1.13 EPS. The business’s revenue was up 15.0% compared to the same quarter last year. As a group, analysts forecast that ANI Pharmaceuticals will post 5.29 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Recommended Story: Short Selling

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.